Che-Yuan Wu, Carina Iskander, Christa Wang, Lisa Y Xiong, Baiju R Shah, Jodi D Edwards, Moira K Kapral, Nathan Herrmann, Krista L Lanctôt, Mario Masellis, Richard H Swartz, Hugo Cogo-Moreira, Bradley J MacIntosh, Jennifer S Rabin, Sandra E Black, Refik Saskin, Walter Swardfager
BACKGROUND: Sulfonylureas are oral glucose-lowering medications positioned as a second-line therapy for type 2 diabetes. Evidence relating them to cognitive decline has been mixed. The objective was to determine whether sulfonylurea use was associated with a differential risk of dementia compared with dipeptidyl peptidase-4 (DPP4) inhibitor use. METHODS: Using administrative data from residents in Ontario, Canada, adults aged ≥66 years who were new users of a sulfonylurea or a DPP4 inhibitor from June 14, 2011, to March 31, 2021 entered this population-based retrospective cohort study...
May 22, 2023: Journal of the American Geriatrics Society